Vertex Pharmaceuticals (VRTX) Interest & Investment Income (2009 - 2026)

Vertex Pharmaceuticals' Interest & Investment Income history runs 13 years deep, the most recent figure standing at $114.8 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 2.63% year-over-year to $114.8 million; the TTM figure through Mar 2026 stood at $484.8 million (down 9.35% YoY), while the FY2025 annual figure was $490.9 million, down 17.92% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $114.8 million, down from $121.9 million in the prior quarter.
• The five-year high for Interest & Investment Income was $181.2 million in Q1 2024, with the low at $1.6 million in Q1 2022.
• The 5-year median for Interest & Investment Income is $122.6 million (2023), against an average of $115.3 million.
• The sharpest annual moves came in 2023 and 2025: Interest & Investment Income jumped 7562.5% in 2023, then plunged 34.93% in 2025.
• Vertex Pharmaceuticals' Interest & Investment Income stood at $86.0 million in 2022, then jumped by 108.72% to $179.5 million in 2023, then dropped by 28.58% to $128.2 million in 2024, then declined by 4.91% to $121.9 million in 2025, then retreated by 5.82% to $114.8 million in 2026.
• Business Quant data shows VRTX's Interest & Investment Income at $114.8 million in Q1 2026, $121.9 million in Q4 2025, and $125.7 million in Q3 2025.